X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CyclASol (cyclosporine) solubilized in a novel water-free excipient, perfluorobutylpentane, it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: CyclASol
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Details:
Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Vevye
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 17, 2023
Details:
Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear evaporation.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: NOV'03
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SENJU PHARMACEUTICAL CO LTD
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 13, 2023
Details:
Vevye (cyclosporine ophthalmic solution) is solubilized in a novel and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Vevye
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: Miebo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bausch & Lomb Incorporated
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
CyclASol® consists of cyclosporine solubilized in a novel water-free excipient, perfluorobutylpentane , it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: CyclASol
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: 37926
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Bausch & Lomb Incorporated
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
CyclASol® (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED).
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: CyclASol
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: 37926
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Bausch & Lomb Incorporated
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease.
Lead Product(s): Perfluorohexyloctane
Therapeutic Area: Ophthalmology Product Name: 37926
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Bausch & Lomb Incorporated
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
